| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435024000 | Involving peptidase | 64 |
| 20080199898 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF - The present invention provides for novel reagents whose fluorescence increases in the presence of particular proteases. The reagents comprise a characteristically folded peptide backbone conjugated to two fluorophores such that the fluorophores are located opposite sides of a cleavage site. When the folded peptide is cleaved, as by digestion with a protease, the fluorophores provide a high intensity fluorescent signal at a visible wavelength. Because of their high specificity and their high fluorescence signal in the visible wavelengths, these protease indicators are particularly well suited for detection of protease activity in biological samples, in particular in frozen tissue sections. Thus this invention also provides for methods of detecting protease activity in situ in frozen sections. | 08-21-2008 |
| 20080286820 | Novel phenoxazinone derivatives as enzyme substrates and use thereof as indicator in the detection of microorganisms with peptidase activity - The present invention relates to novel enzymatic substrates with the following general formula: | 11-20-2008 |
| 20090081718 | Protein cleavage method and thereof - The present invention provides a method for cleaving a glycated protein to obtain an amino acid or a peptide efficiently with a protease. By treating the glycated protein with the protease in the presence of a compound represented by R—X, the amino acid or the peptide is obtained by the cleavage. The R represents an alkyl compound with a carbon number of 9 or more, and preferably is straight-chain alkyl or straight-chain acyl with a carbon number of 9 to 16, branched-chain alkyl or branched-chain acyl with a carbon number of 10 to 40 and a main-chain carbon number of 9 to 16, or straight-chain alkyl that is substituted by cycloalkyl (a carbon number of the cycloalkyl ranges from 3 to 8, and a carbon number of the straight chain ranges from 4 to 13), where X is a sugar residue. Moreover, the glycated protein is, for example, glycated hemoglobin, and preferably β-chain N-terminal amino acid or a β-chain N-terminal peptide is cleaved by the protease treatment. | 03-26-2009 |
| 20090098591 | Method of Correlating Marker Molecule Concentration To A Specific Cell Potency Level in Chondrocyte Culture - A method for measuring the potency of tissue culture derived chondrocyte or chondrocyte-like cells by correlating levels of the marker molecules SERPINA1 and MMP3 in culture supernatant with a specific level of cell potency; including a method for analyzing chondrogenic potency in cells re-differentiated from chondrocytes losing their chondrogenic potency, or which are differentiated from cells to receive chondrogenic potency; comprising the steps of ascertaining the correlative value of the level of SERPINA1, MMP3, or SERPINA1 and MMP3 marker molecules with the potency level of cultured chondrogenic or chondrogenic-like cells; measuring the level of SERPINA1, MMP3, or SERPINA1 and MMP3 marker molecules contained in the supernatant of monolayer or 3D matrix cultured chondrogenic or chondrogenic-like cells; and ascertaining the potency level of the cells from the concentration of the marker molecules in the measurement. | 04-16-2009 |
| 20090142788 | SCREENING METHOD USING NEW SUBSTRATE EPHA4 OF GAMMA-SECRETASE - The present invention provides a method of screening for compounds which affect the processing of EphA4 by γ-secretase, comprising the following steps:
| 06-04-2009 |
| 20090162883 | Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof - The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. An enzyme that cleaves the α-secretase site of APP also is provided. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease. | 06-25-2009 |
| 20090186371 | METHOD FOR DETERMINATION OF INFLAMMATORY BOWEL DISEASE - The instant invention provides a method for the differential diagnosis of inflammatory bowel disease which comprises, | 07-23-2009 |
| 20090203060 | EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER - Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens. | 08-13-2009 |
| 20090208993 | Peptide substrates recognisable by a botulinum toxin a, bont/a and the use thereof - The present invention relates to a peptide substrate selectively recognized by botulinum toxin type A, BoNT/A, comprising a Nop-(Z)-Pya fragment in the peptide structure thereof, wherein Z represents an amino acids chain, preferably RA, said fragment being cleaved by said toxin. Said invention also relates to the substrate use, in particular for carrying out methods for detecting, identifying and/or dosing botulinum toxin type A, at very low concentrations (of the order of 20 pg), or inhibitors and/or activators of the metallopeptidase activity of said toxin and thereby making it possible to quantify the power thereof. | 08-20-2009 |
| 20090215103 | GENERATION AND USE OF A CATALOG OF POLYPEPTIDE-RELATED INFORMATION FOR CHEMICAL ANALYSES | 08-27-2009 |
| 20090298109 | METHOD FOR IDENTIFYING BPLP AND OPIORPHIN AGONISTS OR ANTAGONISTS - A method for in vitro functional characterization of Opiorphin derivatives by using highly selective biochemical assays. The method may employ an assay involving contacting an Opiorphin derivative with an enkephalin-inactivating ectopeptidase, such as neutral endopeptidase NEP (EC 3.4.24.11) or aminopeptidase AP-N (EC 3.4.11.2). This method provides a rapid and sensitive assay for measuring activity of these two membrane-anchored ectoenzymes when contacted with Opiorphin derivative by means of a selective fluorescence-based enzyme model. | 12-03-2009 |
| 20100003710 | Electrochemical Assay for the Detection of Enzymes - The invention relates to novel compositions and methods for the detection of enzymes using the nuclear reorganization energy, λ, of an electron transfer process. | 01-07-2010 |
| 20100015653 | Compounds Regulating Calreticulin, KDEL Receptor and/or ERP-57 Cell Surface Exposure and Uses Thereof to Evaluate the Efficiency of a Cancer Treatment - The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell. | 01-21-2010 |
| 20100021951 | Human Brain Carboxypeptidase B - A novel carboxypeptidase and the encoding gene thereof were successfully identified by screening a human hippocampus extract using brain-APP-cleaving activity as an index. This protein and its gene are useful in, for example, preventing, treating, examining, and diagnosing Alzheimer's disease, and such. | 01-28-2010 |
| 20100028926 | Novel enzymatic substrates derived from phenoxazinone and their use as developer in detection of microorganisms with peptidase activity - Novel enzymatic substrates of the general formula below: | 02-04-2010 |
| 20100099128 | NOVEL PEPTIDASE SUBSTRATES - The present invention relates to an enzyme substrate for detecting peptidase activity in microorganisms, of formula (I) below: | 04-22-2010 |
| 20100129844 | AMINOACYLASE 1 ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of Aminoacylase 1 tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. | 05-27-2010 |
| 20100136594 | HIGH-THROUGHPUT ASSAY FOR EVALUATING DIPEPTIDYL PEPTIDASE I ACTIVITY - A method of screening a compound which modulates dipeptidyl peptidase I (DPPI) activities comprises the steps of adding a peptide substrate of DPPI to a reaction mixture which comprises DPPI and a compound, wherein the peptide substrate of DPPI has at least 3 amino acids and binds to a binding site of DPPI in addition to the S | 06-03-2010 |
| 20100184112 | NOVEL AFFINITY BASED METHOD FOR DRUG TARGET IDENTIFICATION - Drug affinity responsive target stability (DARTS) is a novel method of drug target ID with several significant advantages over current techniques. In certain embodiments the method involves contacting a sample comprising one or more protein target(s) with a test agent to form a sample/test agent mixture; contacting the mixture with a protease; and identifying a protein or protein fragment that is protected from proteolysis, wherein the protection from proteolysis is an indicator that the protein or protein fragment binds to or interacts with the test agent. | 07-22-2010 |
| 20100190195 | Use of Hepatitis B X-Interacting Protein (HBXIP) in Modulation of Apoptosis - Novel methods of regulating cellular apoptosis by affecting the interaction of hepatitis B X-interacting protein (HBXIP) with Survivin are described. More specifically, these novel methods of enhancing apoptosis of neoplastic cells comprises inhibiting interaction of hepatitis B X-interacting protein (HBXIP) with Survivin using siRNA or antisense compounds. | 07-29-2010 |
| 20100209955 | Methods For The Delivery Of Toxins Or Enzymatically Active Portions Thereof - The present invention relates to methods, systems, and kits for intoxicating cells, neuronal and non-neuronal cells, with a toxin or fragment thereof. This is done by subjecting toxin substrate and a lipid or polymeric carrier (e.g., DNA uptake facilitating agent) to one or more cells for use in cell based assays. In an aspect, the methods of the present invention allow for high throughput assays and, as such, for the evaluation of drug candidates. | 08-19-2010 |
| 20100209956 | METHODS AND COMPOSITIONS FOR MODULATING HEPATOCYTE GROWTH FACTOR ACTIVATION - The invention provides methods and compositions for modulating hepsin activity and the HGF/c-met signaling pathway, in particular by regulating pro-HGF activation by hepsin. | 08-19-2010 |
| 20100240083 | METHOD FOR THE DETECTION OF THE IN-VIVO ACTIVITY OF NEUROTRYPSIN, USE OF THE METHOD AND USE OF THE C-TERMINAL, 22-KDA FRAGMENT OF AGRIN AS BIOMARKER IN DIAGNOSIS AND MONITORING OF NEUROTRYPSIN-RELATED DISTURBANCES - Method for the detection of the in-vivo activity of neurotrypsin wherein the amount of the 22-kDa-fragment of agrin is measured in a sample taken from a patient and the measured amount of the 22-kDa-fragment of agrin in the sample is used to calculate the activity of neurotrypsin, use of the method for diagnosis and monitoring of neurotrypsin-related disturbances and use of the 22-kDa-fragment of agrin as biomarker for neurotrypsin-related disturbances. | 09-23-2010 |
| 20100261216 | STABILITY TESTING OF ANTIBODIES - Antibodies are biological macromolecules which may be subject to modification and degradation processes. A new LC/MS-based method for separating and characterizing antibody-specific degradation products is described in the present application which comprises an enzymatic digestion step to cleave the heavy chain using the enzyme IdeS. | 10-14-2010 |
| 20100273199 | Methods and Compositions - The invention relates to a method for aiding the diagnosis of a disorder in a subject, said method comprising; providing a sample from said subject wherein the sample comprises blood; assaying at least two characteristics of said sample, said characteristics selected from: the structural composition of a polypeptide comprised by said sample; a metabolite comprised by said sample; and a catalytic activity comprised by said sample, wherein each of said at least two characteristics is determined from a multiplexed analysis of the same sample. The invention also relates to certain compositions. | 10-28-2010 |
| 20100304414 | Methods and Devices for Detecting Methicillin Resistant Staphylococcus Aureus - Provided are methods and devices for detecting methicillin-resistant | 12-02-2010 |
| 20100330600 | HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin. | 12-30-2010 |
| 20110008812 | METHODS AND SUBSTANCES FOR THE DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS - Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis. | 01-13-2011 |
| 20110053198 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR PROLIFERATIVE HEMATOLOGICAL DISORDERS - Provided herein are methods for the diagnosis, prognosis, or management of proliferative hematological disorders and other diseases using profiles of the ubiquitin-proteasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of leukemia patients. | 03-03-2011 |
| 20110053199 | UBIQUITIN PROTEASOME SYSTEM PROFILING AND THE USE THEREOF IN CLINICAL APPLICATIONS FOR CANCER DIAGNOSIS - Provided herein are methods for the diagnosis, prognosis, or management of neoplastic diseases, i.e. cancer, and other diseases using profiles of the ubiquitin-protcasome system determined from acellular body fluids or cell-containing samples. Further provided are methods of predicting response to therapy in certain populations of cancer patients. | 03-03-2011 |
| 20110065141 | Method of Diagnosing Pancreatic Cancer with the Use of N-Binding Type Sugar Chains - The present invention is to provide a novel marker for diagnosing pancreatic cancer, a method for determining if a subject has pancreatic cancer utilizing the marker, etc. The present inventors collected blood from patients of 78 cases in total including patients of 24 cases with pancreaticobiliary-duct benign disorder (16 gallstone cases and 8 pancreatitis cases) and patients of 54 cases with pancreatic cancer, and mass spectrometry was performed on N-linked sugar chains in plasma. From the 74 mass-spectrometric peaks detected, 65 sugar chains were extracted based on the results of PAM analysis. These extracted sugar chains were then used to predict pancreatic cancer or pancreaticobiliary-duct benign disorder, to correctly diagnose 74% cases. Further, a T-test was performed between the two groups, the group of pancreaticobiliary-duct benign disorder and the group of pancreatic cancer, which identified two sugar chains, the sugar chain of m/z 3031 and the sugar chain of m/z 2362, as sugar chains demonstrating significant difference (p<0.05) and exhibiting 2-fold or greater difference in expression levels between the two groups. The rate of correct detection when using these sugar chains was calculated with six classifiers, all of which gave the result of about 70% correct detection. | 03-17-2011 |
| 20110151495 | Method and menstrum for detecting the presence or absence of methicillin resistant staphylococcus aureus (MRSA) in a test sample - A dry mixture, a liquid menstrum, and a method, are described for use in detecting the presence or absence of Methicillin Resistant | 06-23-2011 |
| 20110171676 | ASC AS A MARKER FOR LUNG CANCER - The present invention relates to the assessment of lung cancer. It discloses the use of protein ASC in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or in the follow-up of patients with lung cancer. | 07-14-2011 |
| 20110183365 | Thrombin Generation Determination Method - A method for measuring a generation of thrombin in a sample of whole blood as a function of time includes adding to a sample of whole blood a fluorogenic substrate and a thrombin activator to form an activated sample. A conversion product is permitted to form in the activated sample. Fluorescence is measured as a function of time from a fluorescent group that is released during the formation of the conversion product with the use of a fluorescence detector. The fluorescence detector operates in an extended range mode and has an increased sensitivity. Thrombin generation as a function of time can then be calculated from the measured fluorescence as a function of time. | 07-28-2011 |
| 20110183366 | Methods for achieving a protective ACE2 expression level to treat kidney disease and hypertension - The present invention provides a method for enhancing expression of angiotensin converting enzyme ACE2 in the vasculature of a mammal, particularly in the renal vasculature and podocytes. The method comprises administering to a mammal in need of such enhancement (e.g., a mammal suffering from, or at risk of developing renal damage or hypertension), an amount of an angiotensin II antagonist sufficient to promote a protective level of ACE2 expression in the vasculature of the mammal. Preferably, the angiotensin II antagonist is administered in an angiotensin II blocking amount, more preferably in an amount sufficient to achieve and maintain a desired level of ACE2 expression in the vasculature of the mammal. The methods of the invention are useful for ameliorating kidney damage from diseases, such as diabetes, as well as hypertension. | 07-28-2011 |
| 20110195443 | Screening Method for Identifying Protease Secretion-Deficient Mutants of Microorganisms - A method for identifying a protease secretion deficient strain of a microorganism involves producing a mutant of the microorganism, followed by adding the mutant to gel-filled wells of a microtitration plate, incubating the mutant in the gel-filled wells under conditions call sing the mutant to secrete proteins, separating the mutant from the gel, and measuring activity of a secretion protease of the microorganism in the gel, wherein either (i) the gel is a substrate for the secretion protease or (ii) the gel contains a substrate for the secretion protease. | 08-11-2011 |
| 20110223628 | METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM - The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism. | 09-15-2011 |
| 20110236918 | METHODS FOR CONDUCTING GENETIC ANALYSIS USING PROTEIN POLYMORPHISMS - Methods and processes for conducting genetic analysis through protein polymorphisms, including identification of individuals, establishment of paternity and measurement of genetic diversity and distance. Some illustrative embodiments of methods of the present invention include the identification of peptide biomarkers using proteomic techniques, including liquid chromatography-tandem mass spectrometry from biological samples, using hair, dentin, or bone as a source of the protein to be analyzed. Other illustrative embodiments include the determination of allelic frequency and feasibility of protein polymorphism peptide biomarkers, and the application of these frequencies to allow statistical analysis and population genetics to be applied to collected biological samples. | 09-29-2011 |
| 20110262948 | Methods of Quantifying Methotrexate Metabolites - The present invention provides a method for efficiently converting methotrexate polyglutamates to methotrexate in a cellular extract by contacting the cellular extract with gamma glutamyl hydrolase under conditions suitable for efficient conversion of methotrexate polyglutamates to methotrexate. | 10-27-2011 |
| 20120021447 | ANALYTICAL ROTORS AND METHODS FOR ANALYSIS OF BIOLOGICAL FLUIDS - Devices for generating discrete flow of liquids in response to a driving force, for example centrifugal microfluidic devices for generating discrete flow in response to a constant driving force. The device includes a supply structure for supplying liquid at an inflow rate to a discretization structure in response to a driving force. The discretization structure is shaped to define an outlet and a level to which the discretization structure fills with liquid flowing from the supply structure before dispensing the liquid at an outflow rate through the outlet in response to the driving force. The device is arranged such that the outflow rate from the discretization structure is greater than the inflow rate into the discretization structure, thereby periodically emptying the discretization structure to create a discretized flow from the outlet. The devices find applications in liquid mixing, for example for diluting samples, such as blood plasma samples. | 01-26-2012 |
| 20120058503 | Novel Indicator Platform - A novel indicator platform comprises a plurality of 1H-lndol-3-yl indicator compounds that are capable of converting to a signalophore compound in response to an external stimulus. In one class of indicator compounds, the resulting signalophores are 2-benzylideneindoline compounds that are formed by an intermolecular Aldol-type process; in a further class of indicator compounds, the resulting signalophores are 10H-indolo[1,2-a]indole compounds that are formed by an intramolecular Aldol-type process. The indicators can be used in a wide array of applications relating, for example, to biological systems or optical data storage. | 03-08-2012 |
| 20120122135 | Novel Peptidase Substrates - The present invention relates to the use of a compound of the following formula (I), as an enzyme substrate for the detection of a peptidase activity or as a pH indicator: | 05-17-2012 |
| 20120208225 | MODIFIED PEPTIDE SUBSTRATE - The invention provides novel reagents and methodologies for detecting free versus bound enzyme. It is particularly useful to detect thrombin when it is not bound to A2M in the presence of thrombin bound to A2M by using a modified substrate that is sterically hindered from reacting with the bound thrombin. | 08-16-2012 |
| 20130078661 | Compounds and Methods for FRET Based Measurement of Enzyme Activity - Provided are compositions and methods for Fluorescence/Forster Resonance Energy Transfer (FRET) analysis of cleavage of Von Willebrand Factor (VWF) polypeptides by the metalloprotease ADAMTS13. The polypeptides contain: i) a first fluorescent protein ii) a VWF amino acid sequence and iii) a second fluorescent protein. The VWF amino acid can contain any of a variety of amino acid substitutions. The method involves contacting a sample that contains ADAMTS13 and using FRET based measurements to determine ADAMTS13 cleavage of the recombinant polypeptide. | 03-28-2013 |
| 20130095515 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 04-18-2013 |
| 20130143251 | EXPEDITIOUS SYNTHESIS OF UBIQUITINATED PEPTIDE CONJUGATES - The present invention discloses a process for preparing ubiquinated peptide conjugates comprising a ubiquitin peptide residue UR attached at its C-terminus to a substrate peptide via a native isopeptide bond, this process comprising combining Native Chemical Ligation (NCL) and solid phase peptide synthesis (SPPS). Further are disclosed ubiquinated peptide conjugates containing a native isopeptide bond, as well as various uses thereof. | 06-06-2013 |
| 20130344525 | Quantitation of GCP Activity in Biological Samples - Provided herein are methods for quantitating glutamate carboxypeptidase II activity in a biological sample, such as a skin biopsy sample, and for determining whether an agent is inhibiting GCP in a subject. | 12-26-2013 |
| 20140045205 | GLUTAMYL AMINOPEPTIDASE AS A MARKER OF RENAL DAMAGE - The present invention relates to a method and a kit for the diagnosis and/or prognosis of kidney injury comprising analysing a sample obtained from a patient and determining the activity of at least one aminopeptidase selected from aspartyl aminopeptidase, glutamyl aminopeptidase, alanyl aminopeptidase and leucyl-cystinyl aminopeptidase. | 02-13-2014 |
| 20140065652 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 03-06-2014 |
| 20140072992 | Di- and Poly-Ubiquitin Deubiquitinase Substrates and Uses Thereof - Methods for detection of the activity of proteolytic enzymes, particularly isopeptidases, are disclosed. | 03-13-2014 |
| 20140273050 | METHODS OF MEASURING CELL VIABILITY IN TISSUE ENGINEERED PRODUCTS - This invention provides methods of measuring the viability of cultured cells by detecting one or more cell death-stable proteins or enzyme activities. Methods provided by the invention correlate viability to relative levels of enzyme activity in cell-containing and non-cell-containing fractions of a cell culture. | 09-18-2014 |
| 20150132786 | METHOD FOR MEASURING GLYCOSYLATED HEMOGLOBIN, MEASUREMENT REAGENT, AND MEASUREMENT KIT - Described is a method for accurately and highly sensitively measuring glycated hemoglobin in a hemoglobin-containing sample without being influenced by hemoglobin. It is related to a method for measuring glycated hemoglobin in a hemoglobin-containing sample, comprising: reacting hemoglobin-containing sample with a protease in the presence of a surfactant; and then reacting the obtained reaction product with fructosyl peptide oxidase, wherein the latter reaction or both of the former reaction and the latter reaction are performed in the presence of a halogen oxide, and measuring the generated hydrogen peroxide. The method for measuring glycated hemoglobin in a hemoglobin-containing sample provided by the present invention is useful in, for example, the measurement of glycated hemoglobin useful in the diagnosis of diabetes mellitus. | 05-14-2015 |
| 20160002702 | BLUE COLLAGENASE ASSAY - A method of measuring soluble or insoluble cell or tissue-associated collagenase activity. The substrate includes native (fibrillar) collagen fragments that were stained with Coomassie Brilliant Blue R-250. Incubation with collagenase can be observed in real-time by the generation of digested smaller fragments. The degraded blue fragments are obtained by filtration through class fibers, onto which intact collagen fibrils are retained. The filtrate containing the blue collagen fragments is incubated with a detergent in order to extract the blue dye, and the mixture is centrifuged in order to separate the dye in the supernatant from the pellet, which contains de-stained collagen fragments and other insoluble materials contained in the test samples (such as bacterial cells or tissues). The amount of dye extracted is quantified by measuring the amount of dye extracted from these fragments, i.e., the absorbance at 600 nm using a spectrophotometer or an ELISA reader. | 01-07-2016 |
| 20160017403 | QUANTIFICATION OF MISFOLDED TNFR2:FC - The present invention is directed to methods for determining the relative amount of wrongly disulphide bridged TNFR2:Fc in a sample of TNFR2:Fc, a fusion protein which is used in a variety of therapeutic applications. In addition, the invention pertains to a method for purifying TNFR2:Fc using said method for determining the percentage of wrongly disulphide bridged TNFR2:Fc, and to TNFR2:Fc compositions obtained thereby. | 01-21-2016 |
| 20160018384 | TRANSLOCATION OF A POLYMER THROUGH A NANOPORE - Embodiments of the present disclosure are directed to methods, systems and devices, for analyzing the molecules. For example, in some embodiments, a system is provided which includes a first volume of conducting fluid, a second volume of conducting fluid, an orifice in communication with said first and second volumes of fluid, and means for applying an electric potential difference between said first and second volumes of fluid. In some such embodiments, a conjugate product is provided which comprises charged polymers each having attached thereto at least one first molecule for analysis, where the product carries a predetermined charge greater than the charge on the first molecule, and upon dissolving a product in the first volume of fluid, the product is directed into the orifice. | 01-21-2016 |
| 20160041184 | IDENTIFICATION AND MONITORING OF MONOCLONAL IMMUNOGLOBULINS BY MOLECULAR MASS - Disclosure herein are methods for determining whether or not an immunoglobulin is present above the polyclonal background level in a biological sample, and methods for determining whether an immunoglobulin contains a kappa or lambda light chain. These methods are useful for screening biological samples for the presence or absence of monoclonal gammopathy, and for diagnosing and monitoring monoclonal gammopathy in a subject. | 02-11-2016 |
| 20160047819 | METHOD FOR DIAGNOSING VAGINAL INFECTIONS - Diagnostic methods for evaluating vaginal infections comprising the use of specific proteins are described. Also described here is the use of specific proteins in a diagnostic method for evaluating recovery from the infections following antibiotic treatment of vaginal infections and predicting the recovery and remission of the infection. Diagnostic methods involving the use of specific proteins for evaluating recovery from the vaginal infections following rifaximin treatment and predicting the recovery and remission of the infection are also described. | 02-18-2016 |
| 20160053297 | THYROGLOBULIN QUANTITATION BY MASS SPECTROSCOPY - Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample. | 02-25-2016 |
| 20160053298 | METHODS FOR IDENTIFYING PROTEINS AND COMPOUNDS THAT MODULATE THE ACTIVITY OF OTUB1 - The present invention describes that OTUB1 cleavage of K48 poly-ubiquitin is stimulated by a select subset of E2 enzymes, and that this stimulation is regulated by the ubiquitin-charged state of the E2 and free ubiquitin. Structural and biochemical studies of OTUB1 and UBCH5B show that the E2 stimulates binding of the polyubiquitin substrate by contacting the OTUB1 N-terminal ubiquitin-binding helix. Methods for identifying E2 enzymes which stimulate or inhibit cleavage of K48 polyubiquitin, as well as novel target compounds which modulate this interaction are provided. | 02-25-2016 |
| 20160103137 | METHOD FOR THE ANALYSIS OF N-GLYCANS ATTACHED TO IMMUNOGLOBULIN G FROM HUMAN BLOOD PLASMA AND ITS USE - The invention discloses a method for the analysis of N-glycans attached to immunoglobulin G (IgG) or IgG N-glycopeptides from human blood plasma in which relative abundance of two or more glycans is determined, out of total six, and for these glycans it is determined that they strongly correlate with age. The glycans have the following structures: | 04-14-2016 |
| 20160130632 | METHODS AND DEVICES FOR DIAGNOSIS OF PARTICLES IN BIOLOGICAL FLUIDS - Methods for determining whether certain compounds, in particular crystals, are present in a sample of a biological fluid that indicates an individual has a particular disease or condition, such as but not limited to gout, pseudogout or urinary tract stones. In some embodiments, the methods include the steps of digestion and filtration of a sample of synovial fluid in order to isolate, if present, monosodium urate monohydrate (MSU), calcium pyrophosphate dihydrate (CPPD), or calcium phosphate crystals from the sample, wherein the filtrate is analyzed with a Raman device to ascertain the presence and type of the crystals. Devices for performing steps of the method are disclosed. | 05-12-2016 |
| 20160138073 | GLYCATED HEXAPEPTIDE OXIDASE AND USE THEREOF - The present invention provides a protein comprising an amino acid sequence in which arginine at position 61 of a protein comprising the amino acid sequence represented by SEQ ID NO: 1 is substituted to an amino acid selected from the group consisting of glycine, alanine, valine, leucine, serine, threonine, proline, cysteine, methionine, asparagine, glutamine, and aspartic acid; and a method for measuring a glycated hemoglobin in a sample, wherein the method comprises reacting a glycated hemoglobin in a sample with a protease to produce a glycated hexapeptide, then reacting the produced glycated hexapeptide with the aforementioned protein, and measuring a substance produced or consumed by the reaction. | 05-19-2016 |
| 20160159885 | INSECT METALLOPROTEINASE INHIBITORS - A polypeptide having at least 70% homology, in particular 80%, 90% or 95% homology to the polypeptide of SEQ ID NO:2 representing the wild-type of the protein insect metalloproteinase inhibitor IMPIα and having at least one mutation at position 35, 36 and/or 39 of the amino acid sequence of IMPIα and the polypeptide having an IC | 06-09-2016 |
| 20190145981 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | 05-16-2019 |
